Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

GREG Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 May 2025 to 30 April 2030
Status
Running
EU funding
€13.3m
Total cost
€26.3m
Partners
57 organisations in 17 countries
Type
Research and Innovation Action
Grant agreement
101191967

What the project is doing

In the project's own words, from its summary on CORDIS.

Europe generates real world health data (RWD) that has the potential to inform the development and evaluation of medicines and medical devices. However, multiple barriers remain that limit the access, analysis, interpretation, and use of RWD, hampering its use. Additionally, the limited uptake of existing guidelines for the generation and use of real world evidence (RWE) adds complexity in the use of RWD to inform decision making.

The GREG consortium will leverage the learnings of previous and ongoing key RWE initiatives to fill these gaps by generating, pilot-testing, and disseminating evidence-based guidance and tools for the use of RWE to inform the development and evaluation of medicines, medical devices, and combinations. To achieve these goals, we will work with key stakeholders to iteratively test and improve our guidance and tools, backed by case studies from previous successful and unsuccessful examples.

We will engage with the most relevant European RWE initiatives and access the largest network of RWD partners in Europe, namely the European Health Data and Evidence Network (EHDEN) through our partner, the EHDEN Foundation. Additionally, we will provide multi-stakeholder gatherings (including patient and public representatives) to promote the dissemination, adoption, and implementation of RWE for decision-making in Europe.

Our public and private partners will co-create use cases working closely with key regulatory and health technology experts in bespoke fora. These will be used initially to evaluate existing guidelines, and later to pilot-test the GREG guidance and tools. Our outputs will include training for all involved stakeholders on the use of our guidance and tools, and practical templates to facilitate regulatory and health technology/payer submissions.

Together, these will accelerate access to better medicines and medical devices for European citizens.

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Sanofi-Aventis gulf F.Z.E.DubaiAEAssociatedpartner
AmgenDiegemBelgiumParticipant
Edwards Lifesciences Belgium BVDilbeekBelgiumParticipant
Sanofi Pasteur Limited CanadaTorontoCanadaAssociatedpartner
Actelion Pharmaceuticals LtdAllschwilSwitzerlandAssociatedpartner
Edwards Lifesciences SARLNyonSwitzerlandAssociatedpartner
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Edwards Lifesciences GmbHGarching B. MunchenGermanyAssociatedpartner
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Pfizer Hellas S.A.AthensGreeceAssociatedpartner
Edwards Lifesciences SLValenciaSpainAssociatedpartner
Instituto Aragones De Ciencias De La SaludZaragozaSpainParticipant
Janssen Cilag SAMadridSpainParticipant
Synapse Research Management Partners SLMadridSpainParticipant
Edwards Lifesciences SASGuyancourtFranceAssociatedpartner
Institut De Recherches Internationales ServierGif-Sur-YvetteFranceParticipant
Medtronic FranceBoulogneFranceAssociatedpartner
Sanofi R&d VaccinsLyonFranceAssociatedpartner
Sanofi Winthrop IndustrieGentillyFranceAssociatedpartner
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Societe Europeenne De CardiologieBiotFranceParticipant
W.L. Gore et Associés S.A.R.L.ParisFranceThird party
University of GalwayGalwayIrelandParticipant
Edwards Lifesciences SRLMilanoItalyAssociatedpartner
Medtronic Italia S.p.A.MilanoItalyAssociatedpartner
W.l. Gore & Associati S.r.l.VeronaItalyParticipant
Erasmus Universiteit RotterdamRotterdamNetherlandsParticipant
Getreal InstituteUtrechtNetherlandsParticipant
Medtronic Bakken Research Center B.v.MaastrichtNetherlandsParticipant
Stichting Eupati FoundationUtrechtNetherlandsParticipant
Stichting European Health Data and Evidence NetworkRotterdamNetherlandsParticipant
The Hyve BVUtrechtNetherlandsParticipant
W L Gore & Associates BVTilburgNetherlandsThird party
Direktoratet for Medisinske ProdukterOsloNorwayParticipant
Universidade De AveiroAveiroPortugalParticipant
Molnlycke Health Care ABGoteborgSwedenParticipant
Pfizer ABSollentunaSwedenAssociatedpartner
Region UppsalaUppsalaSwedenThird party
Aventis Pharma Limited UKReadingUnited KingdomAssociatedpartner
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant
Medtronic LtdWatfordUnited KingdomAssociatedpartner
National Institute for Health and Care ExcellenceManchesterUnited KingdomParticipant
Pfizer LimitedSandwichUnited KingdomAssociatedpartner
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomParticipant
The University of EdinburghEdinburghUnited KingdomParticipant
University of DundeeDundeeUnited KingdomParticipant
Bristol-Myers Squibb Company CorpNew YorkUnited StatesParticipant
Edwards Lifesciences LlcIrvine CaliforniaUnited StatesAssociatedpartner
Janssen Research & Development, LLCRaritanUnited StatesAssociatedpartner
Medical Device Business Services IncWarsawUnited StatesAssociatedpartner
Medical Devices & Diagnostics Global Services, LLCBridgewaterUnited StatesAssociatedpartner
Medtronic, Inc.MinneapolisUnited StatesAssociatedpartner
Pfizer IncNew York CityUnited StatesParticipant
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI